Nanocarriers in Cancer Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 46
Special Issue Editor
Interests: cancer biology and cancer therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Nanocarriers are emerging as a powerful tool in cancer therapy, offering the targeted delivery of therapeutic agents while minimizing side-effects. These nanoscale delivery systems—including organic and inorganic nanoparticles—are engineered to improve the solubility, stability, and bioavailability of anticancer drugs. One of their major advantages is the ability to selectively accumulate in tumour tissues through the enhanced permeability and retention (EPR) effect.
Moreover, nanocarriers can be functionalized with ligands, such as antibodies or peptides or other motifs, to target specific tumour cell receptors, enabling active targeting and further enhancing drug accumulation in cancerous tissues. This targeted approach helps reduce damage to healthy cells, thereby decreasing toxicity and improving patient outcomes. Some nanocarriers are also designed to respond to specific stimuli within the tumour microenvironment—such as pH, enzymes, or temperature—allowing for controlled and localized drug release.
Despite their promise, the clinical translation of nanocarriers faces challenges including large-scale manufacturing, reproducibility, and regulatory approval. Nevertheless, several nanocarrier-based drugs, like Doxil® and Abraxane®, are already FDA-approved, highlighting their potential in advancing precision oncology and improving the efficacy of cancer treatments.
Dr. Wenyi Gu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanoparticles
- cancer therapy
- anticancer drug delivery
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
